Parallel factor ChIP provides essential internal control for quantitative differential ChIP-seq. by Guertin, Michael J et al.
Nucleic Acids Research, 2018 1
doi: 10.1093/nar/gky252
Parallel factor ChIP provides essential internal control
for quantitative differential ChIP-seq
Michael J. Guertin1, Amy E. Cullen2, Florian Markowetz2 and Andrew N. Holding2,*
1Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA
22908, USA and 2Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, Cambridgeshire
CB2 0RE, UK
Received September 11, 2017; Revised March 15, 2018; Editorial Decision March 21, 2018; Accepted March 28, 2018
ABSTRACT
A key challenge in quantitative ChIP combined with
high-throughput sequencing (ChIP-seq) is the nor-
malization of data in the presence of genome-wide
changes in occupancy. Analysis-based normaliza-
tion methods were developed for transcriptomic data
and these are dependent on the underlying assump-
tion that total transcription does not change between
conditions. For genome-wide changes in transcrip-
tion factor (TF) binding, these assumptions do not
hold true. The challenges in normalization are con-
founded by experimental variability during sample
preparation, processing and recovery. We present
a novel normalization strategy utilizing an internal
standard of unchanged peaks for reference. Our
method can be readily applied to monitor genome-
wide changes by ChIP-seq that are otherwise lost
or misrepresented through analytical normalization.
We compare our approach to normalization by to-
tal read depth and two alternative methods that
utilize external experimental controls to study TF
binding. We successfully resolve the key challenges
in quantitative ChIP-seq analysis and demonstrate
its application by monitoring the loss of Estrogen
Receptor-alpha (ER) binding upon fulvestrant treat-
ment, ER binding in response to estrodiol, ER me-
diated change in H4K12 acetylation and profiling ER
binding in patient-derived xenographs. This is sup-
ported by an adaptable pipeline to normalize and
quantify differential TF binding genome-wide and
generate metrics for differential binding at individual
sites.
INTRODUCTION
ChIP combined with high-throughput sequencing
(ChIP-seq) quantifies the relative binding intensity of
protein/DNA interactions genome-wide for a single con-
dition (1–3). However, comparing relative intensities of
binding between samples and between conditions is an
ongoing challenge (4–8). Conventionally, correcting for
sample-to-sample variability between conditions occurs at
the analysis stage (9–12), but these methods assume that
experimental variables remain constant between datasets
and assume comparable genomic binding of the protein
between conditions. In practice, different efficiencies in nu-
clear extraction, DNA shearing and immunoprecipitation
present potential points within a typical ChIP-seq protocol
(13) to introduce experimental variation and error (14).
Analytical normalization methods exist to control for vari-
ability between samples of the same condition (14,15), but
these methods cannot account for experimental variation
between conditions (7). In order to approximate normaliza-
tion between conditions the field has exploited a deficiency
in ChIP-seq. In short, the total read depth is used as a
normalization factor because the vast majority of ChIP-seq
reads are outside of true transcription factor (TF) binding
sites (8,9). Nonetheless, this approach does not control for
any of the aforementioned causes of experimental variabil-
ity and differences in DNA recovery can be interpreted as
differential binding. Previous studies have aimed to resolve
these challenges when analyzing genome-wide changes
through the use of external spike-in controls (4,5). These
methods rely on xenogeneic chromatin (i.e. from a second
organism) and either a second species-specific antibody (5),
or the cross-reactivity of a single antibody to the factor of
interest (4) in both organisms.
Here we present a method, termed parallel-factor ChIP,
that utilizes a second antibody to provide an internal con-
trol. The process of utilizing a second antibody against the
target chromatin avoids the need of a xenogeneic spike-in
and controls for more experimental variables than previ-
ousmethods. In contrast to spike-inmethods, this approach
controls for cell lysis conditions, immunoprecipitation ef-
ficiency and sonication fragment size. Moreover, parallel-
factor ChIP is not dependent upon accurate quantification
of spike-in chromatin.We present thismethod alongside the
application of two xenogeneic methods for the analysis of
the fold-change in TF binding between two conditions. Fur-
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ther, we have developed an adaptable pipeline to apply these
strategies and provide a highly reliable quantitative analysis
of differential binding sites utilizing established statistical
software packages.
Estrogen Receptor-alpha as a model transcription factor
Nuclear hormone receptors are a super-family of ligand-
activated TF. Many of the molecular mechanisms under-
lying well-characterized robust and rapidly inducible tran-
scriptional responses, such as estrogen signaling, are shared
among other systems. Therefore, we use the transcriptional
response to estrogen treatment as a model system to study
TF binding. Moreover, many of the aforementioned nor-
malization challenges are exacerbated in the case of ligand
inducible TFs (7). For our development and comparison of
methods, we monitored ER binding upon treatment with
fulvestrant (16). Accurate analysis of the ER binding is of
key interest as 70% of all breast cancer tumors are classi-
fied as ER+ (17). Fulvestrant is a targeted therapeutic to
prevent the growth of ER+ tumors (18,19). The mode of
action for fulvestrant is to bind to the ER as an antagonist,
which results in recruitment of a different set of cofactors
compared to the native ligand estra-2-diol. The fulvestrant-
specific cofactors promote degradation of the ER (20,21)
via the ubiquitination pathway and the proteasome (22).
The family of compounds to which fulvestrant belongs is
called Selective Estrogen Receptor Degraders or Downreg-
ulators (SERDs). Cellular loss of ER protein results in com-
promised ER binding genome-wide and is thus an ideal
model for the development of novel quantitative ChIP-seq
normalization methods.
MATERIALS AND METHODS
Experimental design
For experiments containing xenogeneic spike-in material,
we generated four replicates for both the control and fulves-
trant treatment, a total of eight samples for the Drosophila
spike-in and eight ChIP-seq samples for the murine chro-
matin spike-in. For the CTCF parallel-factor ChIP exper-
iments, three replicates were prepared for the parallel ER-
CTCF pull-down for both control and treatment, giving a
total of six samples. A single replicate of the CTCF-only
pull-down was prepared for both control and treatment
conditions.
Cell culture
All experimental conditions were conducted in the MCF-
7 (Human, ATCC) cell line. Spike-in standards were gen-
erated using HC11 (Mouse, ATCC) and S2 (Drosophila,
ATCC) cells. MCF-7 were authenticated using STR DNA
profiling.
For each individual ChIP pull-down, 4× 107 MCF-7 cells
were cultured asynchronously, as previously described (23),
across two 15 cm diameter plates in DMEM (Dulbecco’s
Modified Eagle’s Medium, Glibco) with 10% Fetal Bovine
Serum (FBS), Glutamine and Penicillin/Streptomycin
(Glibco). Incubators were set to 37◦C and to provide a hu-
midified atmosphere with 5% CO2.
The cells were treated with either fulvestrant or estradiol
(E2) (final concentration 100 nM, Sigma-Aldrich). Prior to
E2 treatment, cells were washed with phosphate-buffered
saline (PBS) and grown for 4 days in phenol red-free me-
dia supplemented with charcoal-stripped FBS. Media was
changed daily. The cells were then incubated for the appro-
priate time period: 48 h fulvestrant, 2 h for the effect of E2
on H4K12ac or 45 min for ER activation. The cells were
washed with ice cold PBS twice and then fixed by incubat-
ing with 15 ml per plate of 1% formaldehyde in unsupple-
mented clearmedia for 10min. The reactionwas stopped by
the addition of 1.5 ml of 2.5 M glycine and the plates were
washed twice with ice cold PBS. Cells were released from
each plate using a cell lifter and 1 ml of PBS with protease
inhibitors (PI) into a 1.5 ml microcentrifuge tube. The cells
were centrifuged at 8000 rpm for 3 min at 4◦C and the su-
pernatant removed. The process was repeated for a second
wash in 1 ml PBS+PI and the PBS removed before storing
at −80◦C.
S2 cells were grown in T175 flask with Schneider’s
DrosophilaMedium+ 10%FBS at 27◦C. Cells were released
by agitation and transferred to a 50 ml Falcon tube. The
cells were then pelleted at 1300 rpm for 3 min. The media
was removed and the cells resuspended in 7.5 ml PBS. In a
fume hood, cells were cross-linked by the addition of 7.5 ml
2% formaldehyde in unsupplemented clearmedia. The reac-
tionwas stoppedwith 3ml of 1Mglycine at 10min. The sus-
pension of cells was then centrifuged at 2000 × g for 5 min.
The cells were thenwashed twice with 1.5ml PBS+PI before
the PBS+PI was removed and the cells stored at −80◦C.
Untreated HC11 were prepared following the same pro-
cedure as MCF-7.
Chromatin immunoprecipitation (ChIP)
ChIP was performed as previously reported for cell lines
(13) and tissue (23) with the modifications listed below.
For the Drosophila melanogaster chromatin spike-in ex-
periment (sequencing data: SLX-8047), D. melanogaster
andHomo sapiens samples were prepared separately follow-
ing the reported protocol until completion of the sonica-
tion step. Next, the MCF-7 (experimental) chromatin was
combined with the S2 derived chromatin (control) in a ra-
tio of 10:1. Magnetic protein A beads were prepared identi-
cally for both the target antibody (100 g, ER, SC-543, lot
K0113, Santa Cruz) and the control antibody (10 l, H2Av,
39715, lot 1341001). The washed beads were then combined
in a ratio of 1:4 for pull-down. For theMus musculus chro-
matin spike-in experiment (sequencing data: SLX-12998),
M. musculus and H. sapiens cells were prepared separately
following the aforementioned protocol until after sonica-
tion.Next, we combined the chromatin from the experimen-
tal samples (4 × 107 MCF-7 cells) with that from a single
plate of HC11 cells (2 × 106 cells). The protocol was con-
tinued unmodified using only the ER antibody and protein
A beads.
For experiments containing the CTCF antibody con-
trol (sequencing data: SLX-14229, SLX-14438, SLX-15090,
SLX-15091 & SLX-15439), 100 l magnetic protein G
beads were prepared separately for both antibodies, CTCF
(10 l, 3418 XP, Cell Signaling) and ER (100 g, SC-543,
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lots F1716 , F0316 and H1216, Santa Cruz) or H4K12ac
(100 g, 07-595, Lot: 2884543 Millipore). The beads were
then combined 1:1 giving 200 l of beads. The only excep-
tions were the two CTCF controls (one with and one with-
out treatment) where no ER beads were added. These sam-
ples were used to generate a CTCF consensus peak set.
Library prep
ChIP and input DNA were processed using the Thruplex
Library DNA-seqKit (Rubicon) according to the manufac-
turer’s protocol.
Sequencing
Sequencing was carried out by the CRUK Cambridge In-
stitute Genomics Core Facility using a HiSeq 4000, 50 bp
single end reads.
Alignment
Previously, Egan et al. (5) aligned the reads to the genomes
of the two species separately for the generation of correction
factors. We developed our protocol around the alignment
to a single combined reference genome, either Drosophila-
Human (DmHs) orMouse-Human (MmHs). The reference
genomes were generated from Hg19 and Mm9 or Dm3. We
used BowTie2 (version 2.3.2) to align the FASTQ format
reads. This resolves and simplifies the challenge of ambigu-
ous alignments between the two genomes. Reads were re-
moved from blacklisted regions (http://mitra.stanford.edu/
kundaje/akundaje/release/blacklists/).
Peak calling
We used MACS2 (version 2.1.1, default parameters) to call
peaks against the combined genome.An examplewith input
data is provided within the Brundle Example repository in
Git Hub.
Motif analysis was performed using Homer (v4.9) to pro-
vide confidence in peak sets; ER and CTCF control showed
a strong enrichment of the full CTCF motif (P-value ∼
0). Pairwise IDR (irreproducible discovery rate) analysis of
all samples confirmed reproducibility and is summarized in
Supplementary Figures S3, 14C and 16C. QC reports are
summarized in Supplementary Table S3.
qPCR validation of peaks
Loss or gain of ER binding at known ER binding sites
near RARA, NRIP1 and XBP1 were confirmed by ChIP-
qPCR (Supplementary Figure S4) and changes inH4K12ac
was monitored at GREB1, CXCL12 and XBP1. Primers
were as previously reported (24–27). Fold enrichment was
calculated against a control region of the genome, proxi-
mal to TFF1, known to not bind by ER and to be free
of H4K12ac marks from our own ChIP-seq data. The en-
richment values were normalized to an input control. The
primer sequences for the ER unbound control genomic re-
gion were as previously reported (25).
Bioinformatic analysis
The bioinformatic analysis was implemented using R (ver-
sion 3.3.2) with a modified version of DiffBind (version
2.5.6, available from the AndrewHolding/BrundleDevelop
ment repository on GitHub) and DESeq2 (version 1.14.1).
These modifications have been included for the next release
of DiffBind from Bioconductor.
Gene set enrichment analysis
Gene set enrichment analysis of the ER peaks that re-
sponded to fulvestrant treatment (FDR = 0.01) as estab-
lished by the parallel-factor ER-CTCF ChIP were submit-
ted to GREAT (28) for analysis. These gave an enriched es-
trogenic signal (Supplementary Tables S1 and 2).
UCSC Genome browser sessions for the data analy-
sis can be found in the ReadMe.md file uploaded to
the AndrewHolding/Brundle R-Package repository on
GitHub.
Pipeline and R packages
An R package containing the functions used for the
analysis can be installed directly from CRAN or via
AndrewHolding/Brundle on GitHub using the in-
stall github found in the Devtools package.
An R package containing two sets (one internal and
one spike-in control) of test data provided as aligned
reads, peak files and samples sheets can be installed from
AndrewHolding/BrundleData on GitHub.
The complete set of scripts for the preprocessing
pipeline is provided to support the implementation of fu-
ture analysis with Brundle in the preprocessing folder of
AndrewHolding/Brundle Example GitHub. All the con-
tents of the Brundle Example repository are also pack-
aged in a Docker container for easy use. Instructions on
downloading and running the container are available in the
ReadMe.md file.
RESULTS
Analytical normalization methods highlight the need for ex-
perimental quantitative ChIP-seq controls
Three data-based normalization strategies are commonly
used to normalize ChIP-seq binding between conditions:
reads per million (RPM) reads in peaks, RPM total reads
and RPM aligned reads. We applied these methods to each
of our ER ChIP-seq datasets to highlight their deficiencies.
Despite the presence of spike-in chromatin, these analyses
only considered reads that align to the H. sapiens genome.
CTCF binding sites were excluded from the analysis of
parallel-factor ChIP-seq data. We present the analysis of
the xenogeneic spike-in and human/mouse cross-reacting
ER antibody below, but analysis of all datasets gave consis-
tent results and exhibited a strong decrease in ER binding
upon fulvestrant treatment.
We first plotted the average ER peak intensity, as de-
termined by raw counts and three counts-based normal-
ization methods, by the change in ER intensity upon ful-
vestrant treatment (Supplementary Figure S1). In properly
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Figure 1. MA plots showing ER binding before and after treatment with fulvestrant including matched Dm H2Av spike-in control. (A) Reads corrected
to total aligned reads showed the same off-center peak density as observed in the figure. Putative unchanged ER binding sites are within the red triangle.
(B) Overlaying the MA plot combining the changes in chromatin binding of Hs ER (black) and Dm H2Av (blue). Dm peaks overlay the off-center peak
density. (C) Utilizing the DmH2Av binding events as a ground truth for 0-fold-change, a linear fit to the log-fold-change is generated and the fit is applied
to adjust the Hs ER binding events.
normalized MA plots, the unchanged peaks between con-
ditions are distributed with a log-fold difference centered
on zero with increasing variance as the peak intensity de-
creases. However, the distribution of data points in the raw
counts MA plot shows that this distribution is shifted up to
a y-value of ∼1 (Supplementary Figure S1A). We hypothe-
sized that these are true ER binding sites that do not change
upon fulvestrant treatment or false-positive peaks. In both
cases, the apparent increase in binding would therefore be
an artefact of the data processing. As expected, the appar-
ent fold-change for the increase in ER binding was most
pronounced when the data was normalized with respect to
total number of reads in peaks (Supplementary Figure S1B)
because this method is reliant on the majority of binding
events between the two experimental conditions remaining
constant. Other common normalization methods that have
been applied to ChIP-seq data, such as quantile normaliza-
tion (29,30), would result in a similar systematic error in the
final data. More appropriate methods that correct for total
library size, such as RPM total reads, showed little improve-
ment for our datasets over the raw number of reads counts
in peaks (Supplementary Figure S1C). Each normalization
strategy erroneously implies an increase in ER binding to
the chromatin at a large number of sites after 48 h of treat-
ment.
Comparison of existing methods
To confirm that the normalization effects we observed were
typical of the commonly used tools for ChIP-seq analysis,
we compared results from ChIPComp (31), DiffBind (23),
DeSEQ2 (32) andEdgeR (33). In a recent comparative anal-
ysis, ChIPComp and DiffBind were the only two methods
recommended for analysis of narrow peak protein/DNA
binding data (12). We therefore compared the results from
these two pipelines with EdgeR andDeSeq2, which are rou-
tinely applied to ChIP-seq data. The data showed (Supple-
mentary Figure S2) that ChIPComp, EdgeR and DeSEQ2
detect a large number of significantly unregulated ER bind-
ing sites. DiffBind outperformed these methods using to-
tal aligned reads for correction. However, Supplementary
Figure S1C highlights the limitations of using total aligned
reads.
Internal and spike-in normalization controls
Normalization using D. melanogaster chromatin and species-
specific antibody for H2Av. To overcome the challenges
of normalizing ChIP-seq data, Egan et al. (5) combined
the extract with xenogeneic chromatin and a second anti-
body that is specific to the spike-in organism’s chromatin.
This controls for the efficiency of the immunoprecipita-
tion if the same ratio of target to control chromatin is
achieved between samples. This work reported that a reduc-
tion in H3K27me3 in response to inhibition of the EZH2
methyltransferase cannot be detected by standard normal-
ization techniques. Instead, the study demonstrated ge-
nomic H3K27me3 reduction by including D. melanogaster
(Dm) derived chromatin and a Dm-specific histone vari-
ant H2Av antibody as a spike-in control for normalization.
However, this method fails to control for variation in son-
ication fragment length distributions or innaccuracies in
quantifying chromatin concentration.
The challenge in analyzing the genome-wide reduction
in H3K27 methylation by ChIP-seq shares many similari-
ties to quantifying changes in ER binding after fulvestrant
treatment. In particular, both result in a global unidirec-
tional change in chromatin occupancy due to the specific
loss of the target molecule.
We applied this method of normalization to fulvestrant-
depleted ER samples using xenogeneic D. melanogaster
chromatin and an H2Av antibody. Figure 1A shows a sim-
ilar distribution to Supplementary Figure S1C, including
the off-center putative unchanged ER binding events (Fig-
ure 1A, within red triangle) as highlighted in Supplemen-
tary Figure S1A. Overlaying the peak information from the
D. melanogaster peaks indicated that they overlapped along
the same y-axis value (Figure 1B) as the ER binding events
(Figure 1A) that are presumptively unchanged or false pos-
itive peaks. We then applied a linear fit to Dm log2(fold-
change) values for each binding site. The coefficients gener-
ated from the linear regression were then used to adjust the
log2(fold-change) of all data points (Figure 1C). The nor-
malization of the data resulted in a reduced number of in-
creased ER binding events at 48 h. The remaining loci of in-
creased binding resulted from the higher variation at lower
intensities.
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Figure 2. CTCF peak height remains constant while ER peaks change upon treatment with fulvestrant. As the binding of CTCF at the three control peaks
(right) will remain constant in all three conditions, the data is scaled to CTCF peak height. After 100 nM fulvestrant treatment for 48 h, ER binding (left)
shows a reduction in binding at the RARA gene (red) when compared to control (blue). The CTCF peaks can be confirmed against a CTCF only ChIP-seq
experiment (red).
Normalization utilizing ER antibody cross-reactivity and
spike-in murine chromatin. A challenge with using D.
melanogaster spike-in chromatin as a reference standard for
H. sapiens ChIP-seq experiments is that both antibody and
chromatin must be precisely and accurately quantified. This
is technically challenging because cross-linking efficiency,
the fragment size and the protein concentration of H. sapi-
ens chromatin may not be constant between experimental
conditions. In an attempt to reduce the number of variables
that can result in experimental error, we developed a similar
method to that of Bonhoure et al. (6). Their study utilized
the cross-reactivity of a Pol II antibody against Hs control
chromatin and sample chromatin fromM. musculus (Mm).
The ER antibody utilized in this study is known to cross-
react with both Hs and Mm ER homologs. We therefore
expected that the inclusion ofMmchromatin would provide
a series of control data points that would remain constant
between conditions. Unexpectedly, we found that Mm ge-
nomic ER peaks were greatly increased after treatment with
fulvestrant (Supplementary Figure S5A). We compared the
level of Hs and Mm reads between samples and found the
ratios to be consistent (Supplementary Figure S6), which
precludes poor sample balancing as the cause of the results
presented in Supplementary Figure S5.
These results highlight a problem with using a constant
antibody and a xenogeneic source of chromatin for normal-
ization.Despite constant levels ofmouse ER, as the spike-in
cell line was not treated with fulvestrant, we observe an ap-
parent change in ER binding. We propose that the ER anti-
body has lower affinity for mouse ER, compared to human
ER. Therefore, we conclude that the increase in Mm reads
from ER binding sites results from a reduction in competi-
tion with human ER for the same antibody, because fulves-
trant is degrading human ER. These challenges are likely to
be less of a concern when applying this method to a more
conserved target and this explains why there has been pre-
vious success in applying this strategy to the analysis of hi-
stones (5) and RNA Polymerase (6).
Normalization using a second control antibody to provide
an internal control. A key reason for utilizing the cross-
reactivity of antibodies between organisms was to reduce
the number of sources for experimental variation. For the
same reason, we developed the use of a second antibody as
an experimental control to normalize the signal. The ad-
vantages of using a second antibody over a spike-in control
is that the target:control antibody ratio can be maintained
for all samples by producing a single stock solution. For
concurrent experiments, a single stock of antibody-bound
beads can be prepared and used for all samples with mini-
mal variation. For this control to be effective, it is critical to
identify a DNA-binding protein whose genomic distribu-
tion and intensities are not affected by the treatment. For
the analysis of ER binding, we chose CTCF as our control
antibody. While CTCF is affected by compounds that tar-
get ER, the effects of these changes have been documented
at only a small fraction of the total number of sites (34), a
result that was subsequently replicated in our own analysis
(Figure 2; Supplementary Figures S8 and 9B).
We separated the ER and CTCF binding events and plot-
ted them separately on an MA plot (Supplementary Fig-
ure S7A and B). As previously shown for Dm spike-in con-
trol, we applied a global fit to the log2-fold-change between
the two conditions, thereby correcting the bias in fold-
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change between conditions in ER binding (Supplementary
Figure S7C). Taken together, we show that performing a
parallel ChIP-seq experiment with an unrelated and rela-
tively unchanged factor is an alternative and complemen-
tarymethod to account for extreme genomic changes in fac-
tor occupancy.
Pipeline and quantitative analysis
H2Av and CTCF provide a set of unchanged reference peaks
for normalization. For a parallel-factor ChIP to be effec-
tive as an internal control, the majority of the binding sites
for the control factor must not change between the two
conditions. We identified control CTCF peaks from a con-
ventional CTCF ChIP-seq experiment that did not include
ER antibody. Since the signal at CTCF-proximal ER bind-
ing sites may change upon fulvestrant treatment due to the
overlapping signal from ER peaks, we excluded all CTCF
ChIP-seq peaks that are within 500 bp of previously identi-
fied ER binding sites fromMCF-7 cells. Comparison of the
two control datasets (Supplementary Figure S9) displayed a
lower variance and a lowermaximum fold-change for H2Av
compared to theCTCF control binding regions. In contrast,
the CTCF dataset provides a much greater number of data
points for normalization as a result of relative size of the
human andDrosophila genomes. None of the H2Av sites in
the Drosophila genome or CTCF sites used for normaliza-
tion showed a significant change in occupancy.
Normalization implementation using DESeq2 and size fac-
tors. DESeq2 was initially developed for the analysis of
RNA-seq data (32) to provide a method to quantify sig-
nificant differences in gene expression between two sam-
ples by modeling gene counts data with a negative binomial
distribution. Given the similarities in ChIP-seq and RNA-
seq, primarily that they are both based on the same high-
throughput sequencing technologies, DESeq2 has been suc-
cessfully adapted to ChIP-seq analysis to establish differen-
tial intensity analysis of histone modifications.
DESeq2 is designed for an RNA-seq library where to-
tal transcription is assumed to not change between condi-
tions and∼100%of counts are signal (in contrast, theChIP-
seq signal is often contributed by fewer than 5% of reads).
As expected, the default DESeq2 estimateSizeFactors() pa-
rameter calculated from a ChIP-seq counts table distorted
the average change in ER signal because the assumption of
constant total binding between conditions is not met (Sup-
plementary Figure S10A). In the dual antibody Dm spike-
in experiment, the DmH2Av peaks should be constant. We
manually used the read counts in these H2Av control peaks
as a size factors parameter estimate for correcting ER bind-
ing intensities (Supplementary Figure S10B). We processed
the CTCF internal control data in the same manner, using
the counts with CTCF peaks to adjust the size factors pa-
rameter. We normalized the data using the counts within
CTCF peaks to estimate the DESeq2 size factors (Supple-
mentary Figure S11B).
Integration with DiffBind using corrected size factors. Diff-
Bind (23) is an established R package to provide a pipeline
to quantitatively measure differential binding from ChIP-
seq data. DiffBind has been applied to a variety of ChIP-seq
Figure 3. Comparison of mean counts in CTCF peaks before and after
treatment. If the samples have no systematic bias before and after treat-
ment then the linear fit would be expected to have a gradient of 1. Here, we
establish that the gradient is <1, implying a systematic bias between sam-
ples. The read counts in the treated samples peaks are corrected (blue),
removing the bias and resulting in a new gradient of 1.
studies; recent examples include the epigenomic landscapes
of retinal rods and cones (35), the interaction of MDM2
polycomb repressor complex 2 (36) and establishing an en-
vironmental stress response network in Arabidopsis (37). In
a comparative study ofChIP-seq analysis tools,DiffBind re-
liably outperformed other methods (12) and is the preferred
strategy for analysis of ChIP-seq experiments with multiple
replicates. For these reasons, we chose DiffBind to under-
pin our analytical methodology and as a key benchmark
to improve upon. A key feature of DiffBind is that, to cal-
culate size factors, it utilizes the total library size from the
sequence data provided in a sample sheet (e.g. BAM files)
rather than the estimateSizeFactors function provided by
DESeq2. Nonetheless, while improved, the analysis of the
raw data by DiffBind is incomplete with the putative un-
changing peaks showing a>0 log-fold-change (Supplemen-
tary Figure S12). To address this shortcoming, we modified
theDiffBind package to directly calculate the sizeFactor pa-
rameter from a counts matrix of control peaks, in our case
either H2Av or CTCF peaks (Supplementary Figure S12B).
Establishing a normalization coefficient by linear regression
of control peak counts
DESeq2 generates the size factor estimates through the
summation of all reads within the peaks, resulting in a bias
to the peaks with the largest read count. We therefore hy-
pothesized that we could improve normalization by calcu-
lating the sample bias through the application of linear re-
gression. We plot the read count in each CTCF peak of one
condition against the other (Figure 3) and then apply a lin-
ear model to the data. Our normalization coefficient is de-
fined as the constant by which we need to scale the count
data for each CTCF peak from the treated samples to cor-
rect this systematic bias (and thereby setting the gradient
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Figure 4. Comparison of DiffBind results before and after our twomethods of normalization. (A) Normalization to library size. (B) Applying the corrected
size factors from our DESeq2 pipeline generated from CTCF internal control. (C) Applying correction using linear regression of CTCF peaks between
conditions to normalize the data. The result is a 10.7% increase in the number of loci detected as significantly changed ER binding.
of the linear fit equal to 1). This normalization coefficient
is then applied in the same manner to ER count data and
then reinserted into the DiffBind object for analysis.
We compared normalization by total library size, CTCF
control peak-derived size factors, and linear regression to
our sample data. Our linear regression method provided
higher sensitivity, as 10.7% more sites were detected as dif-
ferentially bound (FDR< 0.05) compared to normalization
by library size alone (Figure 4).
Normalization factors are consistent over a wide range in
number of control binding sites
In order to determine if parallel-factor ChIP normalization
could be used with factors that are not pervasively bound
throughout the genome like CTCF, we recalculated the nor-
malization coefficient by sub-sampling from 100% to 1%
of the CTCF peaks. The variability of the result was then
modeled by re-sampling each analysis 100 times (Figure 5).
When sampling only 1% of sites at random, 50% of cases
resulted in an error of <0.5% and the maximum error was
still within 2% of the expected value. This analysis indicates
that parallel factor ChIP is robust and that the number of
control peaks can vary over two orders of magnitude and
not substantially affect the normalization factor.
Normalization of samples with minimal binding condition
In the absence of E2, ER binding to DNA is nearly un-
detectable by ChIP-seq. The minimal level of TF binding
in the initial condition could present a challenge to nor-
malization. To confirm if parallel-factor ChIP was suitable
for application to conditions with a very low level of initial
binding, we applied our pipeline to the analysis of ER bind-
ing in E2-free conditions and 45 min after stimulation with
100 nM E2. The data was normalized using our pipeline
andwe identified 16 884 sites of significantly increased bind-
ing (FDR= 0.05, Supplementary Figure S14A). Analysis of
normalized read depth at known binding sites near RAR,
NRIP1 and XBP1 genes showed an increase in ER bind-
ing as expected (Supplementary Figure S14B). Compari-
Figure 5. Stability of CTCF derived normalization coefficient. Stability of
the CTCFderived normalization coefficient was analyzed by sub-sampling
CTCF peaks before undertaking the calculation (between 1 and 100% of
total sites) at random. This analysis was repeated 100 times to model the
variability of the result.
son of conditions show good correlation between replicates
(Supplementary Figure S14C). Motif analysis of the sites
displaying significantly increased binding gave strong en-
richment for the motifs of the ERE, FOXA1 and GATA3
representing the core ER complex (Supplementary Figure
S14D). Comparison of sites that showed increasedERbind-
ing (FDR = 0.01, Supplementary Figure S15) overlapped
with a core of 1312 conserved sites across four independent
studies and >60% of peaks overlapped with at least 1 other
dataset.
Parallel-factor ChIP to normalize broad histone modification
peaks
Applying parallel-factor ChIP to histone modifications
presents an additional challenge because histone modifica-
tions occur over broad domains, as opposed to the discrete
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Figure 6. Comparison of normalizationmethods using consensus peak set. (A) The analysis for the CTCF normalized (blue) andH2Av normalized (green)
dataset using an ER consensus peak set of 10 000 peaks were formatted as an MA plot and overlaid. This recovered the low-fold-change higher-intensity
peaks that were not visible in Supplementary Figure S7A and both datasets showed a similar distribution. (B) Comparison of fold-change values for
individual ER binding sites between two datasets showed that the inclusion of these sites did not appear to affect the correlation (r = 0.77).
binding TFs. To demonstrate the application of parallel-
factor ChIP-seq to histone marks, we applied our method
to H4K12ac in MCF7 cells. ER regulates H4K12 acetyla-
tion through the recruitment of BRD4 (27). Analysis of the
normalized data showed an increase of H4K12ac at 11393
sites and reduction at 4817 sites (Supplementary Figure
S16A), overall resulting in a significant increase (P-value
= 5.7 × 10−12) of the H4K12ac histone mark as expected.
A total of 377 of the individual sites are significant after
multiple testing correction (FDR = 0.05). As no genome-
wide statistical analysis had previously been undertaken at
individual peaks, we cannot compare this result; however,
included in those 377 significant sites were GREB1 (FDR
= 2.7 × 10−4) and XBP1 (FDR = 3.0 × 10−6) peaks near
their respective transcription start site (TSS), as previously
reported (27). Analysis by qPCR of H4K12ac of GREB1,
CXCL12 and XBP1 sites (Supplementary Figure S16B),
along with the H4K12ac occupancy profile ±3000 bp of
ER Binding (Supplementary Figure S16D), agreed with a
previous report (27). As H4K12ac is commonly associated
with transcription (38) and previous work reported that ER
recruits BRD4 to increase H4K12 acetylation at active pro-
moters (27), we repeated the analysis focusing on H4K12ac
occupancy within ±500 bp of ER binding at transcription
start sites. Under this more stringent filtering, we identi-
fied 497 ER promoter regions with H4K12ac occupancy.
Of these sites, 28 regions were found to have significantly
increased levels of H4K12ac compared to five regions with
decreased (FDR = 0.05) occupancy, equating to ∼6-fold
more sites with increased H4K12ac than had decreased. In
comparison, we observed a ∼2-fold bias genome-wide.
Comparison of absolute fold-change from parallel-factor
ChIP and xenogeneic spike-in
A small subset of high-intensity low-fold-change peaks, i.e.
those at the narrow end of the triangle in Figure 1A, were
absent in the MA plots of samples generated with the par-
allel pull-down of CTCF and ER (Figure 1A and Supple-
mentary S7A). To address if masking of ER binding sites by
CTCFhas a significant impact on the results of ER parallel-
factor ChIP, we re-analyzed the data using a consensus set
of 10 000 high-confidence ER binding sites (as established
by ER-only ChIP). Normalization was carried out as pre-
viously described, either using the Dm chromatin or the
CTCF loci. In principle, if both the internal control using
CTCF binding events and the use of the spike-in Dm/H2Av
control are accurate, the normalized fold-change for each
genomic loci between the two data sets should be equal.
Plotting the fold-change of normalized results from the two
experimental methods (Figure 6) gave a result of near par-
ity between the methods (linear fit of gradient = 0.94) and
a correlation of r = 0.77, with a P-value tending to 0).
Cross-normalization of single-factor ChIP to parallel-factor
ChIP
A potential limitation of parallel-factor ChIP is that CTCF
sites may suppress the fold-change measurement of proxi-
mal TF binding sites. To address this, we made use of an in-
trinsic feature of standard ChIP-seq that the method accu-
rately quantifies relative binding intensities within the same
pull-down. By quantifying TF binding at sites that are not
proximal to CTCF in a parallel-factor ChIP experiment, we
can normalize all sites in a TF-only ChIP. To demonstrate
cross-normalization, we used the Hs reads from the HsDm
dataset as an example of an ER-only ChIP-seq dataset.
We established a set of consensus peaks by matching non-
CTCF proximal ER binding sites from our parallel-factor
ChIP with ER binding sites in our ER-only experiment.
Given that relative binding between sites is intrinsically ac-
curate, by normalizing the ER consensus site binding in
the ER-only experiment to the normalized parallel-factor
ChIP, we were able to accurately normalize all sites in the
ER-only experiment (46). As the ER-only data we used
contained xenogeneic spike-in controls, we were able to
validate the cross-normalization. Comparison of log-fold-
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change after normalization using the xenogeneic spike-in
and cross-normalization showed cross-normalization gave
equivalent results to that previously seen: Pearson’s correla-
tion of 0.992, P-value tending to 0 (Supplementary Figure
S13A). Analysis of ER binding events proximal to CTCF
after cross-normalization showed amarginally greater mag-
nitude of mean and maximal fold-change compared to that
established by parallel-factor ChIP (Supplementary Figure
S13B). We can therefore ascertain that cross-normalization
provides a robust strategy to establish changes in TF bind-
ing; however, in the case of ER binding, the suppressive ef-
fect of proximal CTCF binding is minimal.
Analysis of patient-derived xenografts (PDX) by parallel-
factor ChIP
To demonstrate the versatility of parallel-factor ChIP-seq,
we applied ourmethod to the analysis of five patient-derived
xenografts (PDX) samples. The analysis of PDXs presents
similar challenges to that of clinical material. As a conse-
quence of the high levels of sample heterogeneity, the sam-
ple preparation and immunoprecipitation steps in the ChIP
protocol are significantly more variable than for cell lines.
The low amounts and the high value of samples present fur-
ther challenges by limiting the ability to perform replicate
experiments and analysis.
Analysis of CTCF binding within the samples acted as
a QC step (Supplementary Figure S17A). PDX02 showed
no enrichment at either CTCF or ER binding sites, thereby
confirming the result was not due to low-expression of ER
in the PDX material. The sample was therefore excluded
from further analysis. Clustering of samples by ER binding
events gave two clusters with PDX01 and PDX04 display-
ing the greatest correlation (Supplementary Figure S17B).
A potential reason for the clustering is PDX01 and PDX04
are both derived from PR positive tumors, while PDX05 is
derived from a PRnegative tumor. The PR status of PDX03
is unknown.
Comparison of normalization to total read count (RPM)
and parallel-factor ChIP showed a large disparity between
the two methods at the RARA, GREB1 and CLIC6 ER
binding sites (Supplementary Figure S17C). Analysis of the
variance of the CTCF control peaks proximal to these sites
demonstrated Parallel-Factor ChIP-seq was able to stabi-
lize the data (Supplementary Figure S17D) while normal-
ization to total read count gave little improvement over the
raw data. PDX05 was found to have the lowest levels of ER
bound at the sites investigated.
Genome-wide profiling of the parallel-factor ChIP-seq
PDX data was in agreement with the analysis of individal
promoters. CTCF binding was normalized between sam-
ples (Supplementary Figure S18, top) and gave a consis-
tent profile. ER binding genome-wide was then normalized
on the basis of the correction established from CTCF bind-
ing. Before normalization, all four samples displayed dif-
ferent maximum levels of ER binding. After normalization
PDX01, PDX03 and PDX04 gave similar levels of ER bind-
ing, all derived from tumors with an Allred (39) score of
8 (an immunohistochemical score out of 8 estimating the
proportion and intensity of ER-staining in tumor cells).
In agreement with the analysis of RARA, GREB1 and
CLIC6 ER binding sites, PDX05’s binding profile showed
a reduced maximum level of binding. These results are in
agreementwith the PDX05 being derived froma tumorwith
an Allred score of 5 (Supplementary Figure S18, bottom).
DISCUSSION
We have described a normalization strategy using internal
ChIP-seq controls. We applied this technique to normalize
TF binding in amodel system and patient derived xenograft
samples. Moreover, we developed and implemented a sta-
tistical analysis at the level of individual binding sites,
which was lacking from previous spike-in methodologies.
We demonstrate that a parallel-factor control antibody is
a reliable alternative to previously described experimental
controls (4,5).
We showed that an internal parallel-factor control is com-
parably quantitative to using a second antibody and xeno-
geneic chromatin as a spike-in control, but there are many
advantages to using a second antibody (CTCF) that IPs
a protein within the same extract. Primarily, the parallel-
factor ChIP controls for the greatest number of steps in the
process and gives fewer opportunities for variation being in-
troduced into the sample preparation. In contrast, the ad-
dition of xenogeneic chromatin relies on the precision that
the concentration of the chromatin of both the experimen-
tal samples and the spike-in can be established reliably and
must be added to each sample individually. As chromatin
is routinely cross-linked for ChIP-seq, the resultant mix-
ture of protein and DNA makes accurate quantification of
DNA challenging without purification, which presents an-
other challenge for the use of xenogeneic spike-in methods.
Limitations
Normalization has over-promised the ability to directly
compare different ChIP-seq experimental conditions, an
aim that is intrinsically challenging due to the inherent bio-
logical and environmental variability between experiments.
As a result, inconsistency between ER ChIP-seq in previ-
ous datasets is an ongoing challenge (40). While parallel-
factor ChIP provides an essential normalization between
conditions, it should be understood that the method can-
not control for large-scale biological and environmental fac-
tors. To demonstrate these challenges, we compared our re-
sults with three independent studies and found substantial
overlap of our ER binding events (>60%) with those previ-
ously reported. Further filtering for conserved ER binding
across all four studies gave a core of 1312 sites (Supplemen-
tary Figure S15), improving on a previous comparison of
similar datasets which gave only 284 (40). Nonetheless, this
core set of binding events represents less than 10% of signif-
icant binding sites we identified at an FDR= 0.05. This low
level of reproducibility between studies highlights the need
to understand that biological and environmental variability
is distinct from the technical variability for which parallel-
factor ChIP is designed to control. The key challenge our
method resolves is providing a value of fold-change from
differential analysis that is accurate and comparable be-
tween experiments, which has not previously been possible
with analytical normalization (7). Once the fold-change for
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each peak has been established, then we can undertake di-
rect comparison of fold-change between datasets through
the use of consensus peak sets (Figure 6).
The reliability of any experimental control is critical for
any normalization technique. For the parallel-factor ChIP
peaks, we undertook triplicate biological replicates. If one
was to require the CTCF peak to appear in every replicate,
this would result in over 54 000 high-confidence peaks in our
test dataset. Analysis of the stability of the normalization
coefficient showed only a small fraction of this number of
sites is needed with<2%maximal error when using only 1%
of CTCF peaks (Figure 5). Nonetheless, due to the key role
that normalization plays in the downstream data analysis,
the quality of the data obtained should be assessed by a QC
pipeline, e.g. ChIPQC (41) and NGS-QC (42).
Importantly, our use of normalization controls appears
resilient to changes in antibody batch. There are genuine
concerns in reproducibility of ChIP-seq as a result of batch
variation in antibody. We were able to demonstrate strong
correlation between the xenogeneic spike-in and parallel-
factor controls despite the two experiments being con-
ducted with different lots of ER antibody (see ‘Materials
and Methods’ section) and at different times. Nonetheless,
the initial differential analysis that establishes normalized
fold-change should be performed with the same batch and
source of antibody.
Parallel-factor ChIP has broad utility in the chromatin
and transcription fields. First, we established the ability to
normalize signal from samples that have effectively no de-
tectable binding in the initial condition. We exhibited this
ability using the extreme example of a nuclear receptor that
is nearly entirely unbound in the ligand-free condition. Sec-
ondly, we showed that this approach effectively normalizes
histone modification ChIP-seq data, which presents a dis-
tinct set of challenges (7). We were able to reliably nor-
malize both ER and H4K12ac ChIP-seq signal to the con-
trol factor that was immunoprecipitated in parallel (CTCF).
Previous studies provided evidence of a global increase in
H4K12ac. Through the application of parallel-factor ChIP,
we were able to monitor changes in individual regions of
H4K12ac genome-wide. In agreement with Nagarajan et al.
(27), we found average occupancy of H4K12ac increases;
however, we showed the increase is coupled with a global re-
distribution of H4K12ac not previously described. Analyt-
ical normalization would typically suppress measurement
of the global increase in H4K12ac, yet the use of parallel-
factor ChIP enabled the quantitative analysis of the increase
in the H4K12ac histone mark while simultaneously provid-
ing evidence of the redistribution of H4K12ac histone oc-
cupancy. This exemplifies the power of the internal controls
provided by parallel-factor ChIP. Without these controls,
we would have been unable to reconcile our more detailed
analysis with the results presented by Nagarajan et al.
Experimental normalization is essential and complementary
to analytical normalization
Normalization at the analysis stage has developed consider-
ably since early ChIP-seq experiments; recent examples in-
clude ChIPComp (31), csaw (11) and HMCan-diff (15). In
contrast to analytical normalization, the development of ex-
perimental sample controls is more limited (4–6,8). Exper-
imental normalization, including parallel-factor controls,
remain necessary as analytical normalization of pull-down
efficiency is only possible between replicates of the same ex-
plicit condition (14,15). Without experimental controls to
provide a reference, any systematic bias between conditions
will remain indistinguishable from biological signal.
ER response to fulvestrant
The only previous ChIP-seq study of the effects of fulves-
trant on ER binding (43) identified 10 205 ER binding sites
in the control condition. The ER binding was compared to
tamoxifen (8855 peaks) and fulvestrant (4285 peaks) treat-
ments and concluded the presence of ligand-specific bind-
ing. This result has since been disputed in the context of the
tamoxifen treatment (44). The majority of the tamoxifen-
specific peaks were reassigned as ER peaks by Hurtado
et al. and, of the remaining tamoxifen-specific sites, only
seven were found in both studies and therefore not repro-
ducible. Our analysis of ER binding identified 13 745 sites
in the control condition under the more stringent require-
ments. After normalization, we found no evidence that ful-
vestrant induced ligand-specific binding at 48 h after treat-
ment. Given a single replicate, it is not possible to estab-
lish a statistical test of binding at each site from the Wel-
boren et al. dataset. Our analysis found 10 705 (FDR <
0.05) differentially bound sites, which is substantially more
than previously identified. Gene Set Enrichment Analysis
with GREAT (28) confirmed consistency with the literature
as there was significant enrichment for the ER pathways for
both the MSigDB pathway and perturbation datasets.
Importance of experimental normalization
Normalization has played a key role in these analyses as,
before normalization, our analysis found sites that would
be considered to have significantly increased ER binding
on fulvestrant treatment. Further, as we repeated the ex-
periment with two different normalization techniques, we
can confidently state that, in the context of asynchronous
MCF7 cells, fulvestrant does not result in any significantly
increased binding after 48 h of treatment.
We have shown, as parallel-factor ChIP-seq utilizes inter-
nal standards, our protocol can be applied to the analysis of
tumor samples, PDXs and other clinical material. Consis-
tent sample preparation is a key challenge in clinical sam-
ple studies; and by controlling for variation in cell lysis, im-
munoprecipitation and sonication efficiency, parallel-factor
ChIP allows for the deconvolution of biological signal from
variability in sample preparation in a way that is not possi-
ble with spike-in normalization methods. As implemented
here, one couldmonitor if individuals who are heterozygous
for DNAbinding proteins have absolute reduced binding or
if the absolute levels of TF binding increase during disease
progression.
Integration with existing methods
Most importantly, we have developed the analysis tools to
integrate the normalization strategies described into well-
established quantitative ChIP-seq analysismethods (32). By
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providing an open and reproducible pipeline, we permit oth-
ers the ability to accurately normalize TF binding. We ex-
pect future studies of TFs that undergo rapid and genome-
wide changes will find the methods we present essential
to accurately characterize biological effects. Our analysis
tools, combined with the benefits and relative simplicity of
parallel-factor ChIP to normalize ChIP-seq data, have pro-
vided a fundamental resource for quantitative TF analysis.
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